The Brussels International Declaration on Lipoprotein(a) Testing and Management
There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union. The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.
Authors
- Magdalena Daccord
- Kausik K. Ray (ORCID: https://orcid.org/0000-0003-0508-0954)
- Leslie J. Donato (ORCID: https://orcid.org/0000-0003-0126-7623)
- Marius Geantă (ORCID: https://orcid.org/0000-0003-1510-8885)
- Zanfina Ademi (ORCID: https://orcid.org/0000-0002-0625-3522)
- Albert Wiegman (ORCID: https://orcid.org/0000-0001-6223-5671)
- Mariko Harada‐Shiba (ORCID: https://orcid.org/0000-0002-7600-2059)
- Neil F. Johnson (ORCID: https://orcid.org/0000-0002-3224-3213)
- George Thanassoulis (ORCID: https://orcid.org/0000-0002-9930-7189)
- Pablo Corral (ORCID: https://orcid.org/0000-0003-0017-8725)
- Jean-Luc Eiselé
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Raul Dias Santos (ORCID: https://orcid.org/0000-0002-9860-6582)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Iñaki Gutiérrez‐Ibarluzea (ORCID: https://orcid.org/0000-0002-4080-7963)
- Zhenyue Chen (ORCID: https://orcid.org/0000-0002-4329-5940)
- Samia Mora (ORCID: https://orcid.org/0000-0001-6283-0980)
- Elsie Evans
- John Lane
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Erik S.G. Stroes (ORCID: https://orcid.org/0000-0001-9555-6260)
- Florian Kronenberg (ORCID: https://orcid.org/0000-0003-2229-1120)
- Sayaka Funabashi (ORCID: https://orcid.org/0000-0002-3673-4941)
- Michal Vráblík (ORCID: https://orcid.org/0000-0002-7226-1926)
- Hayato Tada (ORCID: https://orcid.org/0000-0002-3357-1809)
- Masayuki Yoshida (ORCID: https://orcid.org/0000-0002-4600-4504)
- Michel R. Langlois
- Nicola Bedlington
- Ivan Pećin
- Ioanna Gouni-Berthold
- Tobias Silberzahn
- Marc Rijken
- Bogi Eliasen
- Emma Broome
- Michele Calabrò
- Annelies Dol
- Renate Kaal-Poppelaars
- Arthur Rodenbach
- Michelle Winokur
- Aedan Kaal
Institutions
- Kanazawa University (JP)
- Brigham and Women's Hospital (US)
- Foundation for Biomedical Research (US)
- European Union (BE)
- University Hospital Centre Zagreb (HR)
- Innsbruck Medical University (AT)
- University of Cologne (DE)
- Baylor College of Medicine (US)
- Kyorin University (JP)
- Charles University (CZ)
- Hospital Israelita Albert Einstein (BR)
- Ghent University Hospital (BE)
- European Federation of Pharmaceutical Industries and Associations (BE)
- University of South-Eastern Norway (NO)
- Ruijin Hospital (CN)
- McGill University Health Centre (CA)
- Gentofte Hospital (DK)
- Tokyo Metropolitan Institute of Medical Science (JP)
- Health Action International (NL)
- Mayo Clinic in Arizona (US)
- FH Foundation (US)
- Universidad Fraternidad de Agrupaciones Santo Tomás de Aquino (AR)
- Canon Foundation in Europe (NL)
- European Atherosclerosis Society (SE)
- Public Health Service of Amsterdam (NL)
- Australian Centre for Heart Health (AU)
- Amsterdam University Medical Centers (NL)
- University Hospital Cologne (DE)
- European Federation of Nurses Associations (BE)
- General University Hospital in Prague (CZ)
- Imperial College London (GB)
- Monash University (AU)
- University of Amsterdam (NL)
- Osaka University of Pharmaceutical Sciences (JP)
- World Heart Federation (CH)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.119218
- Citations
- 48
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 96.31
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Ultragenyx Pharmaceutical
- PTC Therapeutics
- European Federation of Pharmaceutical Industries and Associations
- Amarin Corporation
- Anthera
- Medicines Company
- Kowa Company
- Amryt Pharma
- InfraRedx
- Imperial College London
- Daiichi-Sankyo
- Novo Nordisk
- Siemens Healthineers
- Swedish Orphan Biovitrum
- HLS Therapeutics
- Silence Therapeutics
- Esperion Therapeutics
- Seqirus
- Genentech
- Abbott Diagnostics
- Daiichi Sankyo Europe